| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/05/2007 | CA2634094A1 Pharmaceutical formulations of fenofibrate having improved bioavailability |
| 07/05/2007 | CA2634093A1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| 07/05/2007 | CA2634088A1 Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| 07/05/2007 | CA2634084A1 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
| 07/05/2007 | CA2634061A1 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| 07/05/2007 | CA2634053A1 Compositions comprising polycation-complexed protein crystals and methods of treatment using them |
| 07/05/2007 | CA2634017A1 Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods |
| 07/05/2007 | CA2633993A1 Phytosterols for use in reducing c-reactive protein levels |
| 07/05/2007 | CA2633992A1 Pyrimidine derivatives useful as inhibitors of pkc-theta |
| 07/05/2007 | CA2633962A1 Dimers and adducts of 6-[(substituted) phenyl] triazolopyrimidines useful as anticancer agents |
| 07/05/2007 | CA2633958A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 07/05/2007 | CA2633929A1 Water-soluble benzoazepine compound and its pharmaceutical composition |
| 07/05/2007 | CA2633825A1 Lansoprazole orally disintegrating tablets |
| 07/05/2007 | CA2633805A1 Treatment methods using triaryl methane compounds |
| 07/05/2007 | CA2633686A1 Compositions and methods for preventing or treating inflammatory bowel disease |
| 07/05/2007 | CA2633684A1 Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) |
| 07/05/2007 | CA2633655A1 Topical mecamylamine formulations for ocular administration and uses therof |
| 07/05/2007 | CA2633653A1 Heterocyclic derivatives as modulators of ion channels |
| 07/05/2007 | CA2633638A1 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, processes for the preparation thereof, and uses thereof |
| 07/05/2007 | CA2633608A1 Long term weight maintenance |
| 07/05/2007 | CA2633584A1 Glucokinase activators |
| 07/05/2007 | CA2633536A1 Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives |
| 07/05/2007 | CA2633500A1 Compounds, screens, and methods of treatment |
| 07/05/2007 | CA2633379A1 Substituted piperidines as calcium channel blockers |
| 07/05/2007 | CA2633369A1 Transdermal delivery of meptazinol |
| 07/05/2007 | CA2633367A1 Aryl-isoxazol-4-yl-imidazole derivatives |
| 07/05/2007 | CA2633361A1 Compositions and methods for attenuating mitochondria-mediated cell injury |
| 07/05/2007 | CA2633356A1 Pharmaceutical composition containing donepezil hydrochloride, tablets produced therefrom and method for producing the same |
| 07/05/2007 | CA2632595A1 Rnai-mediated inhibition of hif1a for treatment of ocular angiogenesis |
| 07/05/2007 | CA2632540A1 Lyophilized compositions of a triazolopyrimidine compound |
| 07/05/2007 | CA2632508A1 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| 07/05/2007 | CA2632262A1 Method of using .beta.-hydroxy-.beta.-methylbutyrate |
| 07/05/2007 | CA2632256A1 Combination of an iap-inhibitor and a taxane7 |
| 07/05/2007 | CA2632239A1 Control of cci-779 dosage form stability through control of drug substance impurities |
| 07/05/2007 | CA2632213A1 Oral formulations comprising tigecycline |
| 07/05/2007 | CA2631840A1 Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma |
| 07/05/2007 | CA2631838A1 Use of anecortave acetate as an adjunct during filtration bleb surgery |
| 07/05/2007 | CA2631686A1 Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate |
| 07/05/2007 | CA2631661A1 Nitroimidazole compounds |
| 07/05/2007 | CA2631632A1 Methods of treating gastrointestinal tract infections with tigecycline |
| 07/05/2007 | CA2630334A1 Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| 07/05/2007 | CA2629342A1 (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
| 07/05/2007 | CA2628728A1 21-deoxymacbecin analogues useful as antitumor agents |
| 07/05/2007 | CA2627729A1 Novel forms of tiotropium bromide and processes for preparation thereof |
| 07/05/2007 | CA2626839A1 5-aryl isoxazolines for controlling invertebrate pests |
| 07/05/2007 | CA2625858A1 Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof |
| 07/05/2007 | CA2623250A1 Fluorinated compounds |
| 07/05/2007 | CA2620142A1 Pure and stable tiotropium bromide |
| 07/05/2007 | CA2611293A1 Process for the preparation of tetrazolyl compounds |
| 07/05/2007 | CA2606289A1 Antimicrobial therapy for bacterial infections |
| 07/04/2007 | EP1804062A2 YKL-40 as a marker and prognostic indicator for cancers |
| 07/04/2007 | EP1803821A2 Methods for managing kinase inhibitor therapy |
| 07/04/2007 | EP1803811A1 Chimeric (double) decoy |
| 07/04/2007 | EP1803802A1 Cleansing composition |
| 07/04/2007 | EP1803729A1 1-( -d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof |
| 07/04/2007 | EP1803727A1 Improved process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts |
| 07/04/2007 | EP1803724A1 N-substituted hydromorphones and the use thereof |
| 07/04/2007 | EP1803722A1 Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |
| 07/04/2007 | EP1803721A1 Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
| 07/04/2007 | EP1803720A1 Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 07/04/2007 | EP1803719A1 1,5-diheterocycle-1h-triazole derivative |
| 07/04/2007 | EP1803718A1 4-Tetrazolyl-4-phenylpiperidine derivatives for treating pain |
| 07/04/2007 | EP1803717A2 Production of delta 9 tetrahydrocannabinol |
| 07/04/2007 | EP1803714A1 Process for preparing crystalline forms of orlistat |
| 07/04/2007 | EP1803710A1 Pyrimidine derivative condensed with non-aromatic ring |
| 07/04/2007 | EP1803709A1 Proton pump inhibitors |
| 07/04/2007 | EP1803706A1 HIV protease inhibitors based on amino acid derivatives |
| 07/04/2007 | EP1803469A2 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 07/04/2007 | EP1803468A1 Agents for treatment of glaucomatours retinopathy and optic neuropathy |
| 07/04/2007 | EP1803458A1 Use of inorganic salts in the treatment of inflammation |
| 07/04/2007 | EP1803457A1 Pharmaceutical composition containing montelukast |
| 07/04/2007 | EP1803456A1 Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells |
| 07/04/2007 | EP1803455A1 N-thiazol-2-yl-benzamide derivatives |
| 07/04/2007 | EP1803454A1 Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation |
| 07/04/2007 | EP1803453A1 Carbamate antibiotics |
| 07/04/2007 | EP1803452A1 Ester derivative and pharmaceutical use thereof |
| 07/04/2007 | EP1803451A1 Pufa supplements |
| 07/04/2007 | EP1803450A1 Pharmaceutical compositions for the eradication of helicobacter pylori |
| 07/04/2007 | EP1803448A2 Tasted masked veterinary solid compositions |
| 07/04/2007 | EP1803445A2 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/04/2007 | EP1803444A2 A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) |
| 07/04/2007 | EP1803443A2 A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC) |
| 07/04/2007 | EP1803441A1 Pharmaceutical formulations of fenofibrate having improved bioavailability |
| 07/04/2007 | EP1803440A1 Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa) |
| 07/04/2007 | EP1803439A2 Composition for external application containing a diamide derivative |
| 07/04/2007 | EP1802656A1 Tweak receptor |
| 07/04/2007 | EP1802648A2 Betulinol derivatives as anti-cancer agents |
| 07/04/2007 | EP1802644A2 Rnai modulation of apob and uses thereof |
| 07/04/2007 | EP1802643A1 Antiviral oligonucleotides |
| 07/04/2007 | EP1802642A2 Fluorophosphonocinnamic compounds, synthesis and uses for treating disorders caused by oxidative stress |
| 07/04/2007 | EP1802641A2 Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| 07/04/2007 | EP1802636A1 Pi3 kinases |
| 07/04/2007 | EP1802634A2 Thiophens and their use as anti-tumor agents |
| 07/04/2007 | EP1802633A1 Benzothieno[2,3-d]pyrimidine compounds as inhibitors of tyrosine kinase activities of the epidermal growth factor receptors (egfrs) for the treatment of hyperproliferative diseases |
| 07/04/2007 | EP1802631A2 Thienopyridinone compounds and methods of treatment |
| 07/04/2007 | EP1802629A1 Difluoro-substituted imidazopyridines |
| 07/04/2007 | EP1802628A1 Crystalline forms and process for preparing spiro-hydantoin compounds |
| 07/04/2007 | EP1802627A1 Pyrazolo (1,5-alpha) pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists |
| 07/04/2007 | EP1802626A1 Pyrrolotriazine compounds |
| 07/04/2007 | EP1802625A1 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |